INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo IRUXOL® MONO OINTMENT

SCHEDULING STATUS
S1

PROPRIETARY NAME
(and dosage form):

IRUXOL® MONO OINTMENT

COMPOSITION
Each 1 g of ointment contains:
  Collagenase Clostridiopeptidase A 1,20 units
  Proteases 0,24 units
PHARMACOLOGICAL ACTION
A 13.9 Special combinations.

PHARMACOLOGICAL ACTION
Iruxol
® mono ointment produces a gentle, bloodless and practically pain-free enzymatic debridement of wounds. Sloughs are dissolved or separated, thereby facilitating their removal.

INDICATIONS
For wound cleaning in various types of ulcerations and decubitus; in poorly healing wounds and necroses.

CONTRA-INDICATIONS
Additional preparations for topical use should not be applied, since such preparations may influence the activity of Iruxol
® mono ointment.

DOSAGE AND DIRECTIONS FOR USE
If not otherwise prescribed by the physician, Iruxol
® mono ointment is applied once daily in a layer of about 2 mm thickness. The ointment should be in close and even contact with the wound surface. In some cases it may be of advantage to apply the ointment twice daily.
Completely dry and hard crusts should be softened by application of a moist dressing. Necrotic material which has separated should be removed when the dressing is changed. This can be done with gauze, forceps or bathing.
As a matter of routine or for relief of irritation, it may be useful to cover the wound edge with zinc paste or a similar preparation. Iruxol
® mono ointment should be applied according to medical prescription. The end of treatment is determined by the physician.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS
At the beginning of treatment a burning sensation and pain may be felt in the wound surface. This, however, results only in rare cases in discontinuance of treatment. Some patients may show signs of local irritation which may be due to hypersensitivity. In such cases the physician should be consulted regarding the continuance of treatment.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
None known. Treatment is symptomatic and supportive.

IDENTIFICATION
A brownish ointment with a faint characteristic odour.

PRESENTATION
Tubes of 10 g and 30 g

STORAGE DIRECTIONS
Store below 25 °C.
Keep out of reach of children.

REGISTRATION NUMBER
G1633 (Act 101/1965)

NAME AND ADDRESS OF APPLICANT
Knoll Pharmaceuticals South Africa (Pty) Ltd
P.O. Box 3030, Halfway House, 1685.

DATE OF PUBLICATION OF THIS PACKAGE INSERT
20 July 1993

K905/2 BASF Pharma

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004